Charting the Course in TR Care

Innoventric's innovation is built on the firm belief that the heterotopic,
cross-caval approach is key to improving TR treatment and extending
care to the often-overlooked patient population.

Innoventric holds a strong patent portfolio for cross-caval
technologies and continuously innovates to broaden the scope of the
solutions it can offer patients.
Innoventric's innovation is built on the firm belief that the heterotopic, cross-caval approach is key to improving TR treatment and extending care to the often-overlooked patient population.

Innoventric holds a strong patent portfolio for cross-caval technologies and continuously innovates to broaden the scope of the solutions it can offer patients.

Trillium™

Trillium™ is the first-of-its-kind cross-caval device, uniquely designed to address TR in a broad patient population. Featuring multiple valves with a novel hinge design, it serves as a particularly beneficial solution in large and tortuous anatomies.

 

Status: Following a successful First-In-Human (FIH) trial in Europe and excellent results from numerous compassionate use procedures, Trillium™ is currently under an EFS in the US.

Koala™

A cross-caval docking station,

Koala™ is designed for anchoring in both
the SVC and IVC, facilitating the placement of an off-the-shelf valve.

 

Status: Several compassionate cases performed in the EU.

Unica™

Building upon the success of Trillium™, our aim with Unica™ is to extend the spectrum of care to an even broader patient population by adding patients with even smaller anatomies. Unica’s bare metal center structure enables future transseptal procedures, and its intra-luminal valves are designed to allow future valve in-valve procedures, if required.

 

Status: Several compassionate cases performed in the EU and Canada.

Trillium™ FIH study publication will be released by the end of the year, along with a consensus paper summarizing the heterotopic treatment options.
Skip to content